Drug Discovery and Drug delivery system

Francois-Xavier Frapaise, M.D has over 40 years of international drug development, regulatory ,strategic planning and marketing experience at major pharmaceutical companies including Sanofi, Bayer, Boehringer, Merck and Abbott; he has hold multiple C-level positions (CSO,CMO,CEO) in different Pharmacos in the US and Europe. Until recently ,he was heading Clinical Development, Medical Affairs and Pharmacovigilance at Merck KGaA Biosimilars Division; he has extensive experience of biosimilars development acquired at Boehringer-Ingelheim and Pfenex); his recent focus of interest is Blockchain Technology application in Pharma. He has been the CSO and SVP of Optimer, has served as the CEO of Asphelia Pharmaceuticals, Inc. VP R&D and Corporate Officer of TAP , CMO of Ocera Therapeutics, VP of Scientific Affairs at Abbott International , Head of Medical Affairs at Bayer Europe, Medical Director at Bayer France, VP of R&D at Delagrange, Head of Anti-thrombotics Strategic Marketing at Sanofi, Medical Director at Choay. Dr. Frapaise holds an M.D. degree from Faculté de Médecine Paris and is a INSEAD alumni. Dr. Frapaise holds an academic position at the Thrombosis Research Center (Loyola Medical Center in Maywood (IL). He is part of Boston-based Trestle Compliance leadership team. He now runs a consulting business, based in Paris.

Dr. Frapaise holds an M.D. degree from Faculté de Médecine Paris and is a INSEAD alumni. Dr. Frapaise holds an academic position at the Thrombosis Research Center (Loyola Medical Center in Maywood (IL). He is part of Boston-based Trestle Compliance leadership team.

Ling Peng is a leading expert in developing functional dendrimer nanosystems for drug delivery in biomedical applications.Dr. Ling Peng is a research director at the French National Scientific Research Center (CNRS). She carried her undergraduate study in chemistry at Nanjing University in China, then joined the group of Professor Albert Eschenmoser at Swiss Federal Institute of Polytechnic in Zurich in 1987 for her Ph.D program. After she completed her Ph.D thesis on the synthesis of modified DNA oligonucleotides in 1993, she spent three years as a postdoctoral research fellow in the group of Prof. Maurice Goeldner at Louis Pasteur University in Strasbourg in France, where she developed various photosensitive probes to investigate the functions of cholinesterases and biomembranes.She has successfully established bio-inspired structurally flexible and self-assembling dendrimer nanosystems for drug and nucleic acid delivery. One of the dendrimers developed by her team has been scheduled in clinical trials. Dr Peng has coordinated and participated in different European projects and actively involved in several European CAOST Actions.er research team has been labelled by La Ligue contre Le Cancer in France for the period of 2016-2020, and she was awarded for the Prize of Dr and Mrs Henri Labbé by the French Academy of Sciences in 2017.

Functional Dendrimers for Nucleic Acid Delivery,Triazole Nucleoside Chemistry for Drug Discovery, Molecular Probes and Chemical Biology.

Adam Sabouni is the Managing Partner for PharmaConsultz. He was the Chief Development Officer at Novan Therapeutics. He has served as the Global VP, Pharmaceutical Sciences and Process Development at Stiefel Laboratories. He was responsible for 5 R&D sites and supported 6 Manufacturing facilities in 4 continents. He has 25 years of experience in PD, manufacturing, compliance, and remediation. At Pfizer, he was responsible for the remediation action plan to lift the cGMP-related consent decree. He is a Pharmacist and has a PhD in pharmaceutical sciences from the University of Bonn.

Pharmaceutical Sciences, Regulatory Affairs,Process Development, Pharmaceutical Affairs, R&D, Pharmaceutical Development, Product & Business Development

Dr. Alain L Fymat is a medical-physical scientist and an educator. He is the current President/CEO and Professor at the International Institute of Medicine and Science with a previous appointment as Executive Vice President, Chief Operating Officer and Professor at the Weil Institute of Critical Care Medicine. He was educated at the University of Paris-Sorbonne and the University of California at Los Angeles. He was formerly Professor of Radiology, Radiological Sciences, Radiation Medicine (Oncology), Critical Care Medicine, and Physics at several U.S. and European Universities. Previously, he was Deputy Director (Western Region) of the U.S. Department of Veterans Affairs, Veterans Health Administration (Office of Research Oversight), and Director of the Magnetic Resonance Imaging Center and for a time Acting Chair of Radiology at its Loma Linda, California Medical Center. He has extensively published (~ 425 publications including patents, books & monographs, book chapters, refereed articles). As invited/keynote speaker and member of organizing committees of international congresses and symposia, he has lectured extensively across the USA, Canada, Europe, Africa and Asia. He has been the recipient of numerous research grants from government, academia and private industry, and has consulted extensively with these entities. He is a Board member of several institutions and Health Advisor of the American Heart & Stroke Association (Coachella Valley Division, California). He is Editor-in-Chief, Honorable Editor or Editor of 35 medical-scientific Journals. He published more than 37 articles in different journals.

Interface between science and medicine, particularly nanomedicine, nanobiotechnology, cancer/oncology, molecular/personal/precision medicine, human genetics/ epigenetics/ ecogenetics, neurodegenerative diseases, and pharmacogenomics, nanotechnology and cancer, nanochemotherapy, nanoneurology, natural and synthetic immunotherapy, drug delivery across the brain protective barriers, and neurodegenerative disorders.

Jens C. Hahne studied chemistry and biochemistry in Freiburg im Breisgau (Germany). He received his PhD in biochemistry from the Albert-Ludwigs- University Freiburg im Breisgau (Germany) in 2000. After working in the field of oncology and translational research at several medical centres in Bonn (Germany), Würzburg (Germany) and at the Charité Berlin (Germany) he is now scientist at the Institute of Cancer Research in London (UK). He received a broad training and knowledge in molecular pathology and cancer research. At the moment, he is working in the Department of Molecular Pathology at the ICR (London, UK). He has published more than 65 papers in reputed journals and has been serving as an Editorial Board Member of repute.

Role of transcription factors for angiogenesis, tumour invasion and metastasis, Tumours, Interaction of tumour cells and cells of the tumour stroma

Allen’s current role is the Senior Vice President of ACT Genomics based in Singapore. Allen has extensive experience across the full spectrum of healthcare industries. He holds concurrent appointments as President of the International Society of Pharmacoeconomics and Outcomes Research (ISPOR) Singapore Chapter and Advisor of Department of Health Promotion, Ministry of Health and Welfare (MOHW) in Taiwan. Prior to joining ACT Genomics, Allen was the principal consultant at IMS Health for Health Economics and Outcomes Research, Real World Evidence Solutions, spearheading the development of IMS Institute Asia, holding dual-roles within ESSEC Business School, as the Co-Director of the Masters of Science in Management of Health Industries and the Director of Institute of Health Economics and Management.

Precision Oncology, Cancer Genomics, Health Economics, Market Access, Corporate Governance

Mohamed Eddouks is Professor at Moulay Ismail University, Faculty of Sciences and Techniques Errachidia, Morocco. He is a researcher in Physiology and Pharmacology with a Master Degree in Metabolic and Molecular Endocrinology from University of Paris vi, a specialized certificate in Endocrine Pharmacology from University of Paris vii and PhD degrees in Physiology and Pharmacology from University of Liege, Belgium and Sidi Mohammed Ben Abdellah University, Fez, Morocco. After his post-doctoral fellowship at Department of Physiology, Faculty of Medicine of Montreal, Canada, he is working for the last 16 years on medicinal plants. His work on antidiabetic and antihypertensive plants is well recognized globally. His research focuses on ethnobiological as well as pharmacological issues in the use of Moroccan medicinal plants for the treatment of diabetes mellitus, obesity and hypertension. His contribution to this field includes four international books and more than 80 peer-reviewed articles and book chapters of international repute. He is Guest Editor of American Journal of Pharmacology and Toxicology, Lead Guest Editor of an annual special issue published by Evidence-Based and Complementary Alternative Medicine, Regional Editor of the Following journals: American Journal of Food Technology, Journal of Applied Sciences, Trends in Applied Sciences Research and Singapore Journal of Scientific research, Member of Editorial Board of several international journals. He has been honored with the first Prize of Scientific Research in 2008 by the Moroccan Association of Research and Development and the first Prize of the Federation of Arab Scientific Councils in 2016. He has been the Dean of Polydisciplinary Faculty of Errachidia from 2008 to 2012.

Pharmacology, Physiology,Molecular Endocrinology

Ng Yi Ling studying final year B.Pharm ytudent at International Medical University, Malaysia.She acted as a IMU Student Ambassadors from 2016-2017.And also worked as a Relationship Manager of Malaysia World Health Assembly (MyWHA) 2017

Pharmacy

Dr. Falah H. Hussein is the professor in University of Babylon. He completed his Ph.D. in Physical Chemistry from Nottingham University, England and M.Sc. in Physical Chemistry from University of Salahaddin, Iraq. He has served several positions as Head Assistant of Chemistry Department-College of Science- Sulaimaniyah University, 1979-1980; President of Al-Qadisya University, 1994 and many more. He has more than 50 publications. He is also prestigious members of Head of Scientific Consultant Burean Committee, International Solar Energy Society,

Physical Chemistry, Pharmacy

Dr. Md. Faiyazuddin has over 11 years of experience as a teacher & researcher with expertise in Pharmaceutical Nanotechnology & Clinical Nanomedicine. He is currently Principal of the Bihar College of Pharmacy at Magadh University, Patna, India. He is an associate member of Institute of Nanotechnology, Sterling University, Scotland, British Society of Nanomedicine, University of Liverpool, International Society of Aerosol in Medicine and American Lung Association, Chicago.

Nano Dry powders for Asthma Therapy, Nanoconjugates of botanicals in hepatoprotection, Chemopreventive nanodelivery approaches for Anticancer agents, Lipid Nanoparticles for Skin Delivery of Botanicals, Ocular Nanopharmaceutics

Francois-Xavier Frapaise, M.D has over 40 years of international drug development, regulatory ,strategic planning and marketing experience at major pharmaceutical companies including Sanofi, Bayer, Boehringer, Merck and Abbott; he has hold multiple C-level positions (CSO,CMO,CEO) in different Pharmacos in the US and Europe. Until recently ,he was heading Clinical Development, Medical Affairs and Pharmacovigilance at Merck KGaA Biosimilars Division; he has extensive experience of biosimilars development acquired at Boehringer-Ingelheim and Pfenex); his recent focus of interest is Blockchain Technology application in Pharma. He has been the CSO and SVP of Optimer, has served as the CEO of Asphelia Pharmaceuticals, Inc. VP R&D and Corporate Officer of TAP , CMO of Ocera Therapeutics, VP of Scientific Affairs at Abbott International , Head of Medical Affairs at Bayer Europe, Medical Director at Bayer France, VP of R&D at Delagrange, Head of Anti-thrombotics Strategic Marketing at Sanofi, Medical Director at Choay. Dr. Frapaise holds an M.D. degree from Faculté de Médecine Paris and is a INSEAD alumni. Dr. Frapaise holds an academic position at the Thrombosis Research Center (Loyola Medical Center in Maywood (IL). He is part of Boston-based Trestle Compliance leadership team. He now runs a consulting business, based in Paris.

Dr. Frapaise holds an M.D. degree from Faculté de Médecine Paris and is a INSEAD alumni. Dr. Frapaise holds an academic position at the Thrombosis Research Center (Loyola Medical Center in Maywood (IL). He is part of Boston-based Trestle Compliance leadership team.

Ling Peng is a leading expert in developing functional dendrimer nanosystems for drug delivery in biomedical applications.Dr. Ling Peng is a research director at the French National Scientific Research Center (CNRS). She carried her undergraduate study in chemistry at Nanjing University in China, then joined the group of Professor Albert Eschenmoser at Swiss Federal Institute of Polytechnic in Zurich in 1987 for her Ph.D program. After she completed her Ph.D thesis on the synthesis of modified DNA oligonucleotides in 1993, she spent three years as a postdoctoral research fellow in the group of Prof. Maurice Goeldner at Louis Pasteur University in Strasbourg in France, where she developed various photosensitive probes to investigate the functions of cholinesterases and biomembranes.She has successfully established bio-inspired structurally flexible and self-assembling dendrimer nanosystems for drug and nucleic acid delivery. One of the dendrimers developed by her team has been scheduled in clinical trials. Dr Peng has coordinated and participated in different European projects and actively involved in several European CAOST Actions.er research team has been labelled by La Ligue contre Le Cancer in France for the period of 2016-2020, and she was awarded for the Prize of Dr and Mrs Henri Labbé by the French Academy of Sciences in 2017.

Functional Dendrimers for Nucleic Acid Delivery,Triazole Nucleoside Chemistry for Drug Discovery, Molecular Probes and Chemical Biology.

Adam Sabouni is the Managing Partner for PharmaConsultz. He was the Chief Development Officer at Novan Therapeutics. He has served as the Global VP, Pharmaceutical Sciences and Process Development at Stiefel Laboratories. He was responsible for 5 R&D sites and supported 6 Manufacturing facilities in 4 continents. He has 25 years of experience in PD, manufacturing, compliance, and remediation. At Pfizer, he was responsible for the remediation action plan to lift the cGMP-related consent decree. He is a Pharmacist and has a PhD in pharmaceutical sciences from the University of Bonn.

Pharmaceutical Sciences, Regulatory Affairs,Process Development, Pharmaceutical Affairs, R&D, Pharmaceutical Development, Product & Business Development

Dr. Alain L Fymat is a medical-physical scientist and an educator. He is the current President/CEO and Professor at the International Institute of Medicine and Science with a previous appointment as Executive Vice President, Chief Operating Officer and Professor at the Weil Institute of Critical Care Medicine. He was educated at the University of Paris-Sorbonne and the University of California at Los Angeles. He was formerly Professor of Radiology, Radiological Sciences, Radiation Medicine (Oncology), Critical Care Medicine, and Physics at several U.S. and European Universities. Previously, he was Deputy Director (Western Region) of the U.S. Department of Veterans Affairs, Veterans Health Administration (Office of Research Oversight), and Director of the Magnetic Resonance Imaging Center and for a time Acting Chair of Radiology at its Loma Linda, California Medical Center. He has extensively published (~ 425 publications including patents, books & monographs, book chapters, refereed articles). As invited/keynote speaker and member of organizing committees of international congresses and symposia, he has lectured extensively across the USA, Canada, Europe, Africa and Asia. He has been the recipient of numerous research grants from government, academia and private industry, and has consulted extensively with these entities. He is a Board member of several institutions and Health Advisor of the American Heart & Stroke Association (Coachella Valley Division, California). He is Editor-in-Chief, Honorable Editor or Editor of 35 medical-scientific Journals. He published more than 37 articles in different journals.

Interface between science and medicine, particularly nanomedicine, nanobiotechnology, cancer/oncology, molecular/personal/precision medicine, human genetics/ epigenetics/ ecogenetics, neurodegenerative diseases, and pharmacogenomics, nanotechnology and cancer, nanochemotherapy, nanoneurology, natural and synthetic immunotherapy, drug delivery across the brain protective barriers, and neurodegenerative disorders.

Jens C. Hahne studied chemistry and biochemistry in Freiburg im Breisgau (Germany). He received his PhD in biochemistry from the Albert-Ludwigs- University Freiburg im Breisgau (Germany) in 2000. After working in the field of oncology and translational research at several medical centres in Bonn (Germany), Würzburg (Germany) and at the Charité Berlin (Germany) he is now scientist at the Institute of Cancer Research in London (UK). He received a broad training and knowledge in molecular pathology and cancer research. At the moment, he is working in the Department of Molecular Pathology at the ICR (London, UK). He has published more than 65 papers in reputed journals and has been serving as an Editorial Board Member of repute.

Role of transcription factors for angiogenesis, tumour invasion and metastasis, Tumours, Interaction of tumour cells and cells of the tumour stroma

Allen’s current role is the Senior Vice President of ACT Genomics based in Singapore. Allen has extensive experience across the full spectrum of healthcare industries. He holds concurrent appointments as President of the International Society of Pharmacoeconomics and Outcomes Research (ISPOR) Singapore Chapter and Advisor of Department of Health Promotion, Ministry of Health and Welfare (MOHW) in Taiwan. Prior to joining ACT Genomics, Allen was the principal consultant at IMS Health for Health Economics and Outcomes Research, Real World Evidence Solutions, spearheading the development of IMS Institute Asia, holding dual-roles within ESSEC Business School, as the Co-Director of the Masters of Science in Management of Health Industries and the Director of Institute of Health Economics and Management.

Precision Oncology, Cancer Genomics, Health Economics, Market Access, Corporate Governance

Mohamed Eddouks is Professor at Moulay Ismail University, Faculty of Sciences and Techniques Errachidia, Morocco. He is a researcher in Physiology and Pharmacology with a Master Degree in Metabolic and Molecular Endocrinology from University of Paris vi, a specialized certificate in Endocrine Pharmacology from University of Paris vii and PhD degrees in Physiology and Pharmacology from University of Liege, Belgium and Sidi Mohammed Ben Abdellah University, Fez, Morocco. After his post-doctoral fellowship at Department of Physiology, Faculty of Medicine of Montreal, Canada, he is working for the last 16 years on medicinal plants. His work on antidiabetic and antihypertensive plants is well recognized globally. His research focuses on ethnobiological as well as pharmacological issues in the use of Moroccan medicinal plants for the treatment of diabetes mellitus, obesity and hypertension. His contribution to this field includes four international books and more than 80 peer-reviewed articles and book chapters of international repute. He is Guest Editor of American Journal of Pharmacology and Toxicology, Lead Guest Editor of an annual special issue published by Evidence-Based and Complementary Alternative Medicine, Regional Editor of the Following journals: American Journal of Food Technology, Journal of Applied Sciences, Trends in Applied Sciences Research and Singapore Journal of Scientific research, Member of Editorial Board of several international journals. He has been honored with the first Prize of Scientific Research in 2008 by the Moroccan Association of Research and Development and the first Prize of the Federation of Arab Scientific Councils in 2016. He has been the Dean of Polydisciplinary Faculty of Errachidia from 2008 to 2012.

Pharmacology, Physiology,Molecular Endocrinology

Ng Yi Ling studying final year B.Pharm ytudent at International Medical University, Malaysia.She acted as a IMU Student Ambassadors from 2016-2017.And also worked as a Relationship Manager of Malaysia World Health Assembly (MyWHA) 2017

Pharmacy

Dr. Falah H. Hussein is the professor in University of Babylon. He completed his Ph.D. in Physical Chemistry from Nottingham University, England and M.Sc. in Physical Chemistry from University of Salahaddin, Iraq. He has served several positions as Head Assistant of Chemistry Department-College of Science- Sulaimaniyah University, 1979-1980; President of Al-Qadisya University, 1994 and many more. He has more than 50 publications. He is also prestigious members of Head of Scientific Consultant Burean Committee, International Solar Energy Society,

Physical Chemistry, Pharmacy

Dr. Md. Faiyazuddin has over 11 years of experience as a teacher & researcher with expertise in Pharmaceutical Nanotechnology & Clinical Nanomedicine. He is currently Principal of the Bihar College of Pharmacy at Magadh University, Patna, India. He is an associate member of Institute of Nanotechnology, Sterling University, Scotland, British Society of Nanomedicine, University of Liverpool, International Society of Aerosol in Medicine and American Lung Association, Chicago.

Nano Dry powders for Asthma Therapy, Nanoconjugates of botanicals in hepatoprotection, Chemopreventive nanodelivery approaches for Anticancer agents, Lipid Nanoparticles for Skin Delivery of Botanicals, Ocular Nanopharmaceutics